Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2021-000486-33-FI
EUCTR2021-000486-33-FI
Active, not recruiting
Phase 1

99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging

Turku University Hospital0 sites320 target enrollmentFebruary 18, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancerTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Turku University Hospital
Enrollment
320
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 18, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Histopathologically confirmed high risk (Gleason \=4\+4, PSA \=20 and/ or cT\=3a) acinar or ductal adenocarcinoma of prostate
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 160
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 160

Exclusion Criteria

  • •Subjects who are previously treated due to prostate cancer

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
PSMA-PET/CT for prostate cancer
EUCTR2017-003461-96-BEGhent University Hospital72
Active, not recruiting
Phase 1
18F-PSMA PET in primary prostate cancer.75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients with PIRADS 3 (equivocal disease) and 25 patients with PIRADS 4-5 (highly suspicious for malignancy) will be included in this explorative study.MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-001387-28-NLRadboud University Medical Center75
Completed
Phase 2
18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathology
NL-OMON49534Radboud Universitair Medisch Centrum75
Recruiting
Not Applicable
99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate CancerProstate Cancer
NCT06219746Turku University Hospital320
Completed
Phase 1
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404Prostate Cancer
NCT01654874Molecular Insight Pharmaceuticals, Inc.6